Effect of Recombinant Human Endostatin Combined with GP Regimen on Tumor Markers and Quality of Life in Patients with Advanced Esophageal Cancer
Objective To investigate the effects of recombinant human endostatin combined with GP regimen on tumor markers and quality of life in patients with advanced esophageal cancer.Methods A total of 90 patients with advanced esophageal cancer admitted to the hospital from February 2021 to December 2022 were selected as the study objects, and were divided into a control group and an observation group according to random number table method, with 45 cases in each group.The control group was treated with GP regimen, and the observation group was treated with recombinant human endostatin on the basis of the control group.The clinical efficacy, quality of life, serum factors and tumor markers of the two groups were compared.Results The total effective rate of the observation group was 88.89％, higher than 71.11％ of the control group, and the difference was statistically significant (P<0.05).Before treatment, there were no significant differences in the levels of vascular endothelial growth factor (VEGF), fibroblast growth factor receptor-4 (FGFR-4), carcinoembryonic antigen (CEA) and spinal protein-2 (Spon-2) between the two groups (P>0.05);after treatment, the levels of FGFR4, VEGF, Spon-2 and CEA in the observation group were (125.97±5.20)pg/mL, (152.21±5.18)ng/L, (13.11±0.20)μg/L and (6.34±0.19)ng/mL, respectively, which were lower than (143.54±8.19)pg/mL, (174.97±6.34)ng/L, (15.96±0.23)μg/L, (8.21±0.09)ng/mL in the control group, and the differences between the groups were statistically significant (P<0.05).Before treatment, there were no significant differences in tumor KPS score between the two groups (P>0.05);after treatment, the KPS score of the observation group were (84.92±2.99) points, which was higher than (78.30±1.87) points of the control group, the difference was statistically significant(P<0.05).The one-year survival rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05).Conclusion Recombinant human endostatin combined with GP regimen can effectively improve the short-term survival rate of patients with advanced esophageal cancer and reduce the expression level of tumor markers, which is highly practical.
Advanced esophageal cancerRecombinant human endostatinGP regimenTumor markersQuality of life
NETL
NSTL
万方数据
